Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bemcentinib + Pembrolizumab in advanced lung adenocarcinoma
NCT03184571Phase 2Completed
- Sponsor
- BerGenBio ASA
- Start
- Oct 2017
- Primary completion
- Oct 2022
- Modality
- Small Molecules
- Countries
- 4
01
Overview
Phase 2, open-label trial of bemcentinib in non-small cell lung cancer (NSCLC) (3 cohorts), sponsored by BerGenBio ASA. Primary endpoint: Objective Response Rate at 24 months. Started Oct 2017; status: completed.
02
Drugs
bemcentinib
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT03184571.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03184571.